VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the availability of an AI ...

A stem cell-derived intestine model reveals glycyrrhizin as a potential treatment for inflammatory bowel disease.

A new study published in Stem Cell Reports demonstrates how a human stem cell-derived model of the intestine can be used to ...

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized ...

Researchers have developed a human intestinal cell model that closely mimics the structure and function of the human gut, enabling more precise prediction of drug-induced gastrointestinal toxicity ...

A cell model that replicates the structure and function of the human intestine has been developed, creating an evaluation platform capable of more accurately predicting adverse effects of new drugs.

Weill Cornell Medicine investigators made an unexpected finding about how the immune system normally suppresses inappropriate ...

A new study published today in Stem Cell Reports demonstrates how a human stem cell-derived model of the intestine can be ...

Inflammatory bowel disease (IBD) is a major global health concern, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can ...